Jason Joon Bock Lee1, Seo Hee Choi1, Jung Ho Im1, Jinsil Seong2. 1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea (Republic of). 2. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea (Republic of). jsseong@yuhs.ac.
Abstract
PURPOSE: Reirradiation has the potential to provide effective local control of upper abdominal malignancies. This study aimed to evaluate the safety and efficacy of reirradiation for upper abdominal malignancies. METHODS: A total of 42 patients with a history of prior radiotherapy (RT) received reirradiation for abdominal malignancies between 2005 and 2017. Each patient's medical records, contours, and dose distribution for both RT courses were reviewed. The median dose of the prior RT was 50.0 Gy (range, 30.0-60.0 Gy) and the median dose of reirradiation was 45.0 Gy (range, 15.0-75.0 Gy). RESULTS: With a median follow-up of 10.9 months, the median infield-failure-free survival (IFFS) rate was 9.2 months. Gross tumor volume (GTV) significantly related to IFFS in both the univariate (p = 0.009) and multivariate analyses (p = 0.024), and patients with a GTV of <60.0 mL had an improved IFFS (p = 0.001). Four patients experienced ≥grade 3 late toxicities. In the retrospective dose reconstruction analysis in these patients, the cumulative dose to the most exposed 2 cc (D2cc) of the duodenum was >60.0 Gy (range, 60.1-73.7 Gy). In the univariate analysis, the D2cc of the duodenum and a preexisting duodenal ulcer identified using endoscopy prior to reirradiation significantly correlated with late severe toxicity (p = 0.021 and 0.017, respectively). CONCLUSIONS: Reirradiation for upper abdominal malignancies could be safely performed for patients without preexisting gastrointestinal morbidity unless the duodenum received excessive radiation doses. Reirradiation could also provide substantial IFFS, especially for patients with a GTV of <60.0 mL.
PURPOSE: Reirradiation has the potential to provide effective local control of upper abdominal malignancies. This study aimed to evaluate the safety and efficacy of reirradiation for upper abdominal malignancies. METHODS: A total of 42 patients with a history of prior radiotherapy (RT) received reirradiation for abdominal malignancies between 2005 and 2017. Each patient's medical records, contours, and dose distribution for both RT courses were reviewed. The median dose of the prior RT was 50.0 Gy (range, 30.0-60.0 Gy) and the median dose of reirradiation was 45.0 Gy (range, 15.0-75.0 Gy). RESULTS: With a median follow-up of 10.9 months, the median infield-failure-free survival (IFFS) rate was 9.2 months. Gross tumor volume (GTV) significantly related to IFFS in both the univariate (p = 0.009) and multivariate analyses (p = 0.024), and patients with a GTV of <60.0 mL had an improved IFFS (p = 0.001). Four patients experienced ≥grade 3 late toxicities. In the retrospective dose reconstruction analysis in these patients, the cumulative dose to the most exposed 2 cc (D2cc) of the duodenum was >60.0 Gy (range, 60.1-73.7 Gy). In the univariate analysis, the D2cc of the duodenum and a preexisting duodenal ulcer identified using endoscopy prior to reirradiation significantly correlated with late severe toxicity (p = 0.021 and 0.017, respectively). CONCLUSIONS: Reirradiation for upper abdominal malignancies could be safely performed for patients without preexisting gastrointestinal morbidity unless the duodenum received excessive radiation doses. Reirradiation could also provide substantial IFFS, especially for patients with a GTV of <60.0 mL.
Entities:
Keywords:
Duodenum; Gross tumor volume; Local control; Radiotherapy dosage; Toxicity
Authors: Brian D Kavanagh; Charlie C Pan; Laura A Dawson; Shiva K Das; X Allen Li; Randall K Ten Haken; Moyed Miften Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Patrick Kelly; Prajnan Das; Chelsea C Pinnix; Sam Beddar; Tina Briere; Mary Pham; Sunil Krishnan; Marc E Delclos; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-29 Impact factor: 7.038
Authors: Amit K Garg; Xin-Shelley Wang; Almon S Shiu; Pamela Allen; James Yang; Mary Frances McAleer; Syed Azeem; Laurence D Rhines; Eric L Chang Journal: Cancer Date: 2011-02-11 Impact factor: 6.860
Authors: Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang Journal: Head Neck Date: 2008-03 Impact factor: 3.147
Authors: Sophia C Kamran; Lauren C Harshman; Mandar S Bhagwat; Vinayak Muralidhar; Paul L Nguyen; Neil E Martin; Stephanie La Follette; Sarah Faso; Akila N Viswanathan; Jason A Efstathiou; Clair J Beard Journal: Adv Radiat Oncol Date: 2017-01-17
Authors: Waqar Haque; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Milind Javle; Christopher R Garrett; Robert A Wolff; Prajnan Das Journal: Radiat Oncol Date: 2009-11-18 Impact factor: 3.481
Authors: Anita M Werensteijn-Honingh; Petra S Kroon; Dennis Winkel; J Carlijn van Gaal; Jochem Hes; Louk M W Snoeren; Jaleesa K Timmer; Christiaan C P Mout; Gijsbert H Bol; Alexis N Kotte; Wietse S C Eppinga; Martijn Intven; Bas W Raaymakers; Ina M Jürgenliemk-Schulz Journal: Phys Imaging Radiat Oncol Date: 2022-06-30